Oppenheimer & Co’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.95M Buy
12,795
+11,055
+635% +$4.1M 0.05% 364
2026
Q1
$509K Buy
+1,740
New +$572K 0.01% 1185
2025
Q4
Sell
-2,478
Closed -$801K 1630
2025
Q3
$801K Sell
2,478
-3,044
-55% -$947K 0.01% 998
2025
Q2
$2.15M Sell
5,522
-222
-4% -$89.3K 0.03% 552
2025
Q1
$2.5M Buy
5,744
+123
+2% +$49.4K 0.04% 484
2024
Q4
$2.07M Buy
5,621
+122
+2% +$51.1K 0.03% 539
2024
Q3
$2.86M Sell
5,499
-68
-1% -$36.3K 0.04% 431
2024
Q2
$3.02M Sell
5,567
-434
-7% -$229K 0.05% 401
2024
Q1
$3.11M Buy
6,001
+285
+5% +$142K 0.05% 393
2023
Q4
$2.7M Sell
5,716
-154
-3% -$71.2K 0.05% 418
2023
Q3
$2.56M Buy
5,870
+360
+7% +$163K 0.05% 391
2023
Q2
$2.45M Sell
5,510
-1,262
-19% -$582K 0.05% 419
2023
Q1
$3.11M Sell
6,772
-1,095
-14% -$521K 0.07% 326
2022
Q4
$4.04M Sell
7,867
-3,960
-33% -$2.01M 0.09% 265
2022
Q3
$5.37M Sell
11,827
-5,246
-31% -$2.51M 0.13% 199
2022
Q2
$8.24M Sell
17,073
-816
-5% -$404K 0.18% 123
2022
Q1
$8.79M Buy
17,889
+64
+0.4% +$29.3K 0.16% 136
2021
Q4
$8.26M Sell
17,825
-1,022
-5% -$430K 0.14% 148
2021
Q3
$7.03M Sell
18,847
-16,233
-46% -$6.17M 0.13% 170
2021
Q2
$13.4M Buy
35,080
+318
+0.9% +$122K 0.24% 92
2021
Q1
$12.5M Sell
34,762
-130
-0.4% -$41.8K 0.25% 84
2020
Q4
$11.2M Buy
34,892
+230
+0.7% +$70.6K 0.24% 93
2020
Q3
$9.31M Sell
34,662
-1,963
-5% -$528K 0.23% 91
2020
Q2
$9.63M Buy
36,625
+15,215
+71% +$4.06M 0.25% 85
2020
Q1
$4.86M Sell
21,410
-541
-2% -$147K 0.15% 145
2019
Q4
$6.63M Sell
21,951
-498
-2% -$137K 0.16% 135
2019
Q3
$5.39M Buy
22,449
+4,227
+23% +$1.16M 0.15% 156
2019
Q2
$5.14M Buy
18,222
+144
+0.8% +$39.3K 0.14% 167
2019
Q1
$5.19M Sell
18,078
-1,311
-7% -$379K 0.14% 162
2018
Q4
$5.09M Sell
19,389
-45
-0.2% -$12.4K 0.16% 138
2018
Q3
$5.33M Sell
19,434
-550
-3% -$143K 0.14% 178
2018
Q2
$4.76M Sell
19,984
-1,473
-7% -$341K 0.13% 178
2018
Q1
$4.71M Sell
21,457
-2,270
-10% -$533K 0.12% 184
2017
Q4
$5.34M Sell
23,727
-1,513
-6% -$322K 0.14% 175
2017
Q3
$4.79M Sell
25,240
-22
-0.1% -$4.19K 0.13% 184
2017
Q2
$4.75M Sell
25,262
-200
-0.8% -$35.9K 0.13% 185
2017
Q1
$4.21M Buy
25,462
+64
+0.3% +$10.2K 0.12% 206
2016
Q4
$3.65M Sell
25,398
-24,544
-49% -$3.29M 0.11% 225
2016
Q3
$6.26M Sell
49,942
-1,985
-4% -$256K 0.18% 127
2016
Q2
$6.82M Buy
51,927
+189
+0.4% +$25.9K 0.2% 108
2016
Q1
$7.19M Sell
51,738
-6,708
-11% -$896K 0.22% 104
2015
Q4
$8.15M Sell
58,446
-2,791
-5% -$384K 0.24% 97
2015
Q3
$8.57M Buy
61,237
+13,486
+28% +$2.03M 0.26% 84
2015
Q2
$7.84M Buy
47,751
+4,693
+11% +$750K 0.22% 104
2015
Q1
$6.65M Sell
43,058
-2,262
-5% -$322K 0.18% 133
2014
Q4
$5.7M Sell
45,320
-1,238
-3% -$153K 0.16% 151
2014
Q3
$5.57M Sell
46,558
-4,733
-9% -$543K 0.17% 142
2014
Q2
$5.52M Sell
51,291
-21,129
-29% -$2.18M 0.17% 140
2014
Q1
$7.21M Buy
72,420
+29,153
+67% +$2.64M 0.22% 111
2013
Q4
$4M Sell
43,267
-22,648
-34% -$2.01M 0.13% 197
2013
Q3
$5.51M Buy
65,915
+35,995
+120% +$3.08M 0.19% 134
2013
Q2
$2.45M Buy
+29,920
New +$2.24M 0.09% 260

Other funds holding ELV

Oppenheimer & Co's ELV Position: Q2 2026 in Review

Oppenheimer & Co increased its Elevance Health (ELV) stake by 635% in Q2 2026, buying an estimated $4.1M and bringing the position to 12,795 shares worth $4.95M. The position accounts for 0.05% of the portfolio, ranked #364.

Oppenheimer & Co first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.4M in Q2 2021. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Oppenheimer & Co held 12,795 shares of Elevance Health worth $4.95M as of Q2 2026.
  • Oppenheimer & Co bought 11,055 Elevance Health shares in Q2 2026, an estimated $4.1M.
  • Elevance Health made up 0.05% of Oppenheimer & Co's portfolio in Q2 2026, its #364 holding.
  • Oppenheimer & Co first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Elevance Health position peaked at $13.4M in Q2 2021.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.